7/29/2019 SRNS Lapkas Sham & Justin
1/35
CHAPTER 1
INTRODUCTION
1.1. BACKGROUND
The first recorded description of nephrotic syndrome dates to the 15th century. Later,
Volhard and Fahr popularised the term nephrosis, using it to describe a major classification of
bilateral renal disease. Today, nephrotic syndrome is recognised as a common chronic illness in
childhood (Eddy AA & Symons JM, 2003)
The estimated annual incidence of nephrotic syndrome in healthy children is 2 to 7 new
cases per 100,000 children younger than 18 years of age, making it a relatively common major
disease in pediatrics. The peak age of onset occurs at 2 to 3 years except for the rare, congenital
type of nephrosis. Approximately 50% of affected children are ages 1 to 4 years; 75% are
younger than age 10 years. In addition, even the most benign form of the nephrotic syndrome is,
by nature, a recurrent disorder, so each new-onset case likely will continue to manifest disease
for some time. Nephrotic syndrome is one of the most frequent reasons for referral to a pediatric
nephrologist for evaluation, although its insidious onset frequently causes delay in diagnosis.
Careful examination of the anatomy of a nephron permits characterization of the glomerular
basement membrane as the barrier between the circulation and the external environment. Thus,the glomerular membrane, which permits passage in an adult of approximately 180 L/d of fluid,
is the final determinant of how much of the solute originally contained in this volume enters the
tubular lumen. The normal glomerular membrane is remarkably selective for protein compared
with other solutes. Once this selectivity is lost, the ensuing proteinuria defines not only the
diagnosis of nephrotic syndrome, but many pathophysiologic consequences as well (Roth KS et
al, 2002)
Childhood nephrotic syndromes are most commonly caused by one of two idiopathic
diseases: minimal-change nephrotic syndrome (MCNS) and focal segmental glomerulosclerosis
(FSGS). A third distinct type, membranous nephropathy, is rare in children. Other causes of
isolated nephrotic syndrome can be subdivided into two major categories: rare genetic disorders,
and secondary diseases associated with drugs, infections, or neoplasia. The cause of idiopathic
nephrotic syndrome remains unknown, but evidence suggests it may be a primary T-cell disorder
7/29/2019 SRNS Lapkas Sham & Justin
2/35
that leads to glomerular podocyte dysfunction. Genetic studies in children with familial nephrotic
syndrome have identified mutations in genes that encode important podocyte proteins. Patients
with idiopathic nephrotic syndrome are initially treated with corticosteroids. Steroid-
responsiveness is of greater prognostic use than renal histology. Several second-line drugs,
including alkylating agents, ciclosporin, and levamisole, may be effective for complicated and
steroid-unresponsive MCNS and FSGS patients. Nephrotic syndrome is associated with several
medical complications, the most severe and potentially fatal being bacterial infections and
thromboembolism. Idiopathic nephrotic syndrome is a chronic relapsing disease for most steroid-
responsive patients, whereas most children with refractory FSGS ultimately develop end-stage
renal disease. Research is being done to further elucidate the disorders molecular pathogenesis,
identify new prognostic indicators, and to develop better approaches to treatment (Eddy AA,
Symons JM, 2003)
1.1. Objective
The aim of this study is to explore more about the theoretical aspects on Nephrotic
Syndrome, also to emphasis and to integrate the theory and application of Nephrotic Syndrome
case in daily life.
7/29/2019 SRNS Lapkas Sham & Justin
3/35
CHAPTER 2
NEPHROTIC SYNDROME
2.1. DEFINITION OF NEPHROTIC SYNDROME
Thesine qua non of the diagnosis of nephrotic syndrome is the presence of urinary protein, with
the albumin disproportionately greater than the globulin, deriving from a loss of glomerular
membrane selectivity. In the pediatric age group, urinary protein loss of 50 mg/kg per 24 hours
or greater is a firm diagnostic criterion. It is imperative to recognize the distinctive origin of the
proteinuria in the glomerulus rather than the tubule; nephrotic syndrome may be seen as
exclusively glomerular in origin without any associated tubular dysfunction. Additionally, as a
syndrome, the clinical picture may be either primary or secondary, and underlying causes must
be excluded (Roth KS et al, 2002).
The nephrotic syndrome (NS). consisting of massive proteinuria, hypoalbuminemia, edema, and
hyperlipidemia, is a common complication of glomerular disease in children and adults (Tune
BR & Mendoza SA, 1997).
2.2. EPIDEMIOLOGY OF NEPHROTIC SYNDROME
Idiopathic nephrotic syndrome has a reported incidence of two to seven cases per 100 000
children and a prevalence of nearly 16 cases per 100 000. There are three distinct histological
variants of primary idiopathic nephrotic syndrome: minimal-change nephrotic syndrome
(MCNS), focal segmental glomerulosclerosis (FSGS), and membranous nephropathy. MCNS
and FSGS may represent opposite ends of one pathophysiological process or distinct disease
entities. By contrast, membranous nephropathy is a distinct disease associated with prominent
immune complex deposits located between glomerular podocytes and the glomerular basement
membrane. Membranous nephropathy is rare in children (Eddy AA, Symons JM, 2003).
The annual incidence of nephrotic syndrome in most countries in the Western Hemisphere is
estimated to range from 2 to 7 new cases per 100,000 children, and the prevalence is about 16
cases per 100,000 children. There is a male preponderance among young children, at a ratio of
7/29/2019 SRNS Lapkas Sham & Justin
4/35
2:1 to females, although this gender disparity disappears by adolescence, making the incidence in
adolescents and adults equal among males and females (Gbadegesin R & Smoyer WE, 2008).
The incidence of nephrotic syndrome has been fairly stable over the last 30 years, but there are
suggestions that the histopathologic patterns may be changing. For example, reports from
different parts of the world indicate an increasing occurrence of focal segmental
glomerulosclerosis (FSGS) not only after adjusting for variations in renal biopsy practices but
also based on the generous assumption that all patients who did not have a renal biopsy had
minimal change nephrotic syndrome (MCNS) (Gbadegesin R & Smoyer WE, 2008).
Ethnic origin may affect the histological variant and the response to immunosuppressive
treatment. In particular, Hispanic and black patients are more likely to have steroid-unresponsive
nephrotic syndrome than are white patients. Age at initial presentation has an important impact
on the disease distribution frequency. 70% of MCNS patients are younger than 5 years; 2030%
of adolescent nephrotic patients have MCNS. FSGS develops in children at a median age of 6
years. During the first year of life, congenital (birth to age 3 months) and infantile (312 months)
genetic disorders and congenital infections are much more common than MCNS and FSGS.
Inherited forms of steroid-responsive and steroid-resistant nephrotic syndrome are being
increasingly recognised (Eddy AA, Symons JM, 2003).
Not all cases of MCNS or FSGS are idiopathic. MCNS can occur in association with lymphoid
tumours or immunomodulatory drugs. FSGS is the most common histological variant in patients
with HIV nephropathy. Renal lesions resembling idiopathic FSGS may also be present in
proteinuric patients with other primary renal disorders, such as chronic glomerulonephritis,
reflux nephropathy, and oligomeganephronia (Eddy AA, Symons JM, 2003).
2.3. CLASSIFICATION OF NEPHROTIC SYNDROME
Idiopathic (primary) nephrotic syndrome
- Minimal change (80-90%)
- Focal segmental glomerulosclerosis (FSGS) (10-20%)
Secondary nephrotic syndrome (HSP, SLE, MPGN)
Congenital nephrotic syndrome
(Fahmi N, 2011)
7/29/2019 SRNS Lapkas Sham & Justin
5/35
Children who present with the typical features of nephrotic syndrome (see below) are generally
responsive to steroid treatment and a renal biopsy, were it performed, would be likely to show
minimal change nephrotic syndrome. Those with atypical features are more likely to be
unresponsive to steroid treatment, and a biopsy more likely to show FSGS or one of the other
forms of nephrotic syndrome. Therefore children with typical features are started on steroids
without recourse to renal biopsy. Those with atypical features should therefore undergo renal
biopsy before receiving steroid treatment (Fahmi N, 2011).
TYPICAL FEATURES ATYPICAL FEATURES
Age 1-10 years < 1yr, > 10years
Normotensive Hypertensive
Normal Adrenal Function Elevated Creatinine
+/- Microscopic Haematuria Macroscopic Haematuria
2.4. ETIOLOGY OF NEPHROTIC SYNDROME
NO CAUSES OF CHILDHOOD NEPHROTIC SYNDROME
1 Genetic Disorders
Nephrotic Syndrome Typical
- Finnish-type congenital nephrotic syndrome
- FSGS- Diffuse mesangial sclerosis
- Denys-Drash syndrome
- Schimke immuno-osseous dysplasia
Proteinuria with or without Nephrotic Syndrome
- Nail-patella syndrome
- Alports syndrome
Multi system syndromes with or without Nephrotic Syndrome
- Galloway-Mowat syndrome
- Charcot-Marie-Tooth disease
- Jeunes syndrome
7/29/2019 SRNS Lapkas Sham & Justin
6/35
- Cockaynes syndrome
- Laurence-Moon-Biedl-Bardet syndrome
Metabolic disorders with or without Nephrotic Syndrome
- Alagille syndrome
- -1 antitrypsin deficiency
- Fabry disease
- Glutaric acidaemia
- Glycogen storage disease
- Hurlers syndrome
- Lipoprotein disorders
- Mitochondrial cytopathies
- Sickle-cell disease
Idiopathic Nephrotic Syndrome
- MCNS
- FSGS
- Membranous nephropathy
2 Secondary Causes
Infections
- Hepatitis B, C
- HIV-1
- Malaria
- Syphilis
- Toxoplasmosis
Drugs
- Penicillamine
Gold
Non-steroidal anti-inflammatory drugs
7/29/2019 SRNS Lapkas Sham & Justin
7/35
Pamidronate
Interferon
Mercury
Heroin
Lithium
Immunological or Allergic Disorder
- Castlemans disease
- Kimuras disease
- Bee sting
- Food allergens
Associated with Malignant Disease
- Lymphoma
- Leukaemia
Glomerular hyperfiltration
- Oligomeganephronia
- Morbid obesity- Adaptation to nephron reduction
*May also be consequence of inflammatory glomerular disorders, normally associated
with features of nephritiseg, vasculitis, lupus nephritis, membranoproliferative
glomerulonephritis, IgA nephropathy.
(Allison A Eddy, Jordan M Symons., Nephrotic syndrome in childhood, THE LANCET, Vol
362, August 23, 2003)
2.5. PATHOGENESIS OF NEPHROTIC SYNDROME
7/29/2019 SRNS Lapkas Sham & Justin
8/35
The pathogenesis of MCD is unclear, but there is a strong evidence of immune dysregulation,
chiefly involving cell-mediated immunity (CMI). The tendency of nephrotic syndrome to
manifest and relapse after viral infections or an atopic episode, the association with HLA
antigens and Hodgkins lymphoma, and the therapeutic response to steroids and cyclosporine A
(CsA) support this view. The occurrence of prolonged remissions following measles, which
downregulates CMI further endorses this hypothesis. Abnormalities of T cell subsets and/or
function have been variably reported in a number of patients with MCD9-11. Most of the
functional abnormalities that are described are not specific and might represent an effect (rather
than a cause) of the disease (Bangga A & Mantan M, 2005).
2.5.1 Cytokine bias
Recent knowledge on functional subdivisions of the immune response has been applied to
understand the pathogenesis of nephrotic syndrome. Broadly, antigen presentation to T
lymphocytes results in a polarized immune response, which may be type 1 [dominated by -
interferon, interleukin (IL) 2] or type 2 (IL4, IL10 or IL13). Type 1 cytokines predominate in
cell-mediated immunity and type 2 cytokines in some aspects of humoral immunity. Type 2
cytokines are particularly associated with atopy and class switching of B cells for production of
IgG4 and IgE13. The findings of increased plasma levels of IgE, relatively normal IgG4 (with
decreased IgG1 and IgG2), and association with atopy suggest type 2 cytokine bias in subjects
with MCD. Increased systemic production of representative cytokines, chiefly IL4 is also
reported14. In vitro studies suggest that podocytes express receptors for IL4 and IL1314.
Activation of these receptors, by respective cytokines, might disrupt glomerular permeability
resulting in proteinuria. The clinical benefits on treatment with levamisole, which augments type
1 and downregulates type 2 cytokines also support the above hypothesis (Bangga A & Mantan
M, 2005).
Examination, by immunohistochemistry renal biopsies from 30 consecutive patients with steroid-
resistant nephrotic syndrome (SRNS), secondary to MCD and FSGS, for T cells expressing type
1 or type 2 cytokines.It was found that there was a significantly higher proportion of IL4 and
IL10 bearing T cells compared to those expressing interferon-(IFN-) or IL2. The precise
mechanism/s by which the cytokine bias might affect glomerular permeability is however, not
clear (Bangga A & Mantan M, 2005).
7/29/2019 SRNS Lapkas Sham & Justin
9/35
2.5.2. Nephrotic syndrome a podocytopathy
For many years the attention of researchers was focussed on the glomerular basement membrane
or extraglomerular factors as being responsible for increased glomerular permeability. Recent
evidence suggests that the primary defect in idiopathic nephrotic syndrome might be at the level
of podocyte, the glomerular visceral epithelial cell. Injury to the podocyte can occur in many
immune and non-immune renal diseases. Podocyte injury or structural inherited defects are
increasingly implicated in the occurrence of glomerular proteinuria. Some viruses like HIV,
parvovirus B19 and simian SV40 may directly cause injury to the podocyte (Bangga A &
Mantan M, 2005).
Mutations in genes encoding several podocyte proteins have been identified in children with
familial nephrotic syndrome (Table III). A structurally defective podocyte or deficient basement
membrane protein may result in loss of permselectivity and nephrotic range proteinuria. Such
patients are less likely to respond to immunosuppressive therapy and progress to end stage renal
failure19. The most implicated mutation involves the NPHS1 gene, encoding the protein nephrin.
This transmembrane protein is present in the slit diaphragm between the podocytes (Fig. 1).
Mutations in nephrin are responsible for the congenital Finnish nephrotic syndrome8.
Abnormalities of another gene, the NPHS2 gene encoding podocin, results in recessively
inherited FSGS. This mutation is also found in 10-30 per cent of sporadic onset steroid-resistant
FSGS. The gene for autosomal dominant FSGS has been identified on chromosome 19, encoding
alpha-actinin-4. Some other implicated genes are WT1 (Wilms tumour suppressor gene),
FSGS2 and LMX1B (nail patella syndrome). Mutations in WT1 are associated with Denys-
Drash syndrome (characterized by male pseudohermaphroditism, nephrotic syndrome and
Wilms tumour) and Frasier syndrome (male pseudohermaphroditism, FSGS and
gonadoblastomas). Steroid-sensitive nephrotic syndrome (SSNS) may rarely be familial; a locus
has been mapped to chromosome 1q25, close to but distinct from the podocin gene20. Nephrotic
syndrome with FSGS has also been reported in patients with mitochondrial cytopathies,
presenting with isolated nephrotic syndrome or in association with myopathy, encephalopathy
and lactic acidosis (Bangga A & Mantan M, 2005)
A hypothesis unifying the observed immunological abnormalities, increased glomerular
permeability and evidence of podocyte injury is yet to be proposed. The speculation that critical
7/29/2019 SRNS Lapkas Sham & Justin
10/35
podocyte proteins might be potential targets for T cell cytokines or vascular permeability factors,
though attractive needs confirmation. Availability of tests to detect genetic mutations shall
enable screening of patients with SRNS for such defects in the future. The role of
immunosuppressive medications in subjects with these mutations is limited (Bangga A &
Mantan M, 2005)
2.6. PATHOPHYSIOLOGY OF NEPHROTIC SYNDROME
2.6.1. Proteinuria
Children with MCD, although massively proteinuria, do not have a generalized glomerular leak
to macromolecules. The clearance of neutral macromolecules in MCD is actually less than
normal over a range of molecular radii. In contrast, the clearance of anionic macromolecules is
significantly increased. This and several other lines of evidence suggest that proteinuria results
from a loss of the fixed negative charges of anionic glycosaminoglycans in the glomerular
capillary wall. The mechanism by which these charges are lost has not been defined. A highly
cationic protein in the plasma and urine of children with MCD has been recently described, but
the pathogenic significance of this protein has not been determined (Tune BR & Mendoza SA,
1997).
2.6.2. Oedema
The traditional view has been that massive albuminuria in NS causes a decrease in intravascular
oncotic pressure, which allows extravasation of fluid, resulting in hypovolemia, increased
aldosterone and antidiuretic hormone secretion, and renal salt and water retention. Consistent
with this mechanism are the observations that, in MCD of childhood, edema seldom occurs when
serum albumin levels are above 2.0 g/dL and the elevated hematocrit, prerenal azotemia, and
fluid retention during relapse may be improved by intravenous infusions of salt-poor albumin
(Tune BR & Mendoza SA, 1997).
The principal clinical manifestation of nephrotic syndrome is oedema, the pathogenesis of which
remains controversial. Traditional teaching supports the so-called underfill theory, in which
proteinuria and subsequent hypoalbuminaemia lead to decreased intravascular oncotic pressure.
This pressure results in translocation of plasma water into the interstitial space; secondary
7/29/2019 SRNS Lapkas Sham & Justin
11/35
sodium retention develops to compensate for intravascular volume contraction (Eddy AA,
Symons JM, 2003).
The underfill theory is intuitively attractive and data showing that nephrotic patients have
contracted intravascular volume, reduced glomerular filtration rate, and raised renin and
aldosterone concentrations support the concept. Critics of the underfill theory point to studies in
which some nephrotic patients have normal or even increased intravascular pressure. Plasma
renin activity is not universally increased in nephrotic patients. Volume expansion and head-out
water immersion do not consistently suppress the neurohumoral response and cause natriuresis,
as would be expected if the plasma volume were contracted. The overfill theory, proposed in
response to these criticisms, suggests that the abnormality leading to nephrotic oedema is a
primary defect in sodium excretion. The observation that in rats with unilateral proteinuria,
sodium avidity is increased in only the proteinuric kidney provides experimental support. The
cause of the increased sodium retention remains unknown, but is thought to occur in the distal
tubules, perhaps mediated by resistance to atrial natriuretic peptide (Eddy AA, Symons JM,
2003).
Although the overfill theory is gaining favour, it is not universally accepted and may not be
sufficient to explain oedema formation in childhood nephrotic syndrome. Studies of children
with MCNS in particular report variability in measurements of intravascular volume status. The
underfill and overfill mechanisms are not necessarily mutually exclusive, dependent on the stage
of nephrotic syndrome, the rate of development of hypoproteinaemia, and absolute plasma
oncotic pressure (Eddy AA, Symons JM, 2003).
Children with MCNS frequently present with rapid onset of proteinuria and oedema formation;
intravascular volume contraction (underfill) is common in this acute setting but may be less
operant later in their course. By contrast, patients with chronic forms of persistent nephrotic
syndrome may have continuing sodium retention and thus be more prone to oedema from overfill
mechanisms (Eddy AA, Symons JM, 2003).
Finally. patients with congenital analbuminemia typically have little or no edema. An alternative
explanation for retention of salt and water in NS is a decreased GFR, with a decreased filtration
fraction (Tune BR & Mendoza SA, 1997).
2.6.3. Hyperlipidaemia
7/29/2019 SRNS Lapkas Sham & Justin
12/35
Hyperlipidaemia, with raised serum cholesterol and triglyceride concentrations, is a hallmark of
nephrotic syndrome. This complication results from complex interactions between disordered
lipoprotein metabolism, medications, and dietary factors. Increased hepatic lipoprotein synthesis,
in response to low plasma oncotic pressure, as a consequence of the urinary loss of an as-yet
unidentified regulatory substance, or both, is thought to play a key pathogenetic part. Studies in
experimental nephrotic syndrome models have identified several enzymatic changes that alter
lipid biosynthesis and degradation. These include increased hepatic 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase and acyl-coenzyme A-cholesterol acyltransferase activities,
and decreased cholesterol 7 hydroxylase and lipoprotein lipase activities. Variability of
apolipoprotein (a) may also contribute to differences in lipid concentrations during active
nephrotic syndrome and remission (Eddy AA, Symons JM, 2003).
2.7. DIAGNOSTIC OF NEPHROTIC SYNDROME
2.7.1. Clinical Diagnostic Criteria
The diagnostic criteria are:
1) Generalized edema;
2) Hypoproteinemia (< 2 g/dL [20 g/L]), with disproportionately low albumin in relation to
globulin;
3) Urine protein (mg/dL) to urine creatinine (mg/dL) ratio in excess of 2 in a first morning void
or a 24-hour urine protein that exceeds 50 mg/kg body weight; and
4) Hypercholesterolemia (> 200 mg/dL [5.17 mmol/L]).
The reduced serum albumin, which can fall to as low as 0.5 g/dL (5 g/L), causes a marked
reduction in plasma oncotic pressure. Consequently, circulatory volume is lost to the interstitial
spaces, resulting in generalized edema. Often, the initial swelling is observed as facial (especially
periorbital) and pretibial edema, with prominent swelling of the scrotum or labia also seen. An
additional consequence of the lowered oncotic pressure is reduced perfusion of the splanchnic
capillary bed, which can cause abdominal pain. Pleural effusions may form, and frank pulmonary
edema also may occur, with either or both resulting in tachypnea and chest pain. Levels of serum
cholesterol, triglyceride, and lipoprotein cholesterol are consistently elevated. The mechanism(s)
underlying these changes are not understood completely, in part due to the complexity of lipid
transport and the difficulties inherent in human clinical studies. Increases in very-low density and
7/29/2019 SRNS Lapkas Sham & Justin
13/35
low-density lipoprotein (VLDL and LDL, respectively) cholesterol are characteristic findings.
VLDL-cholesterol is increased as a consequence of decreased hepatic catabolism, thus increasing
circulating triglyceride and cholesterol. LDL-cholesterol is increased due to an enhanced
synthetic rate. What remains to be elucidated is the cause for these disturbances in hepatic lipid
metabolism. Primary nephrotic syndrome may occur at any age, from the neonate to the adult.
The neonatal or congenital nephrotic syndrome, also called Finnish congenital nephrosis, is
clearly defined as a genetic mutation in the nephrin gene and has been mapped to chromosome
19q13.1. Nephrin is a glomerular basement membrane protein that participates in formation of
anionic-rich sites, causing electrochemical repulsion of plasma proteins. The mutation also has
been reported in a Mennonite group in Pennsylvania who have no Finnish heritage and is
believed to have arisen independent of the Finnish type. Primary childhood nephrotic syndrome
rarely appears before 18 months to 2 years of age and peaks in incidence at about 3 years of age
(Roth KS et al, 2002).
2.7.2. Laboratory Findings
The primary laboratory feature of the nephrotic syndrome is a marked proteinuria, in excess of
50mg/kg per 24 hours. The excreted protein is predominantly albumin, although
immunoglobulins (Igs) also are lost. In uncomplicated cases of idiopathic nephrotic syndrome, it
is unusual to see gross hematuria in the presence of proteinuria, although microscopic hematuria
occurs in a sizeable proportion of cases. For patients who have gross hematuria and proteinuria,
IgA nephropathy always must be a diagnostic consideration (Roth KS et al, 2002).
In the presence of clinical edema, measurement of serum protein will yield low values; the serum
albumin is likely to be 2.0 g/dL (20 g/L) or lower. Albumin concentrations as low as 0.5 g/100
mL can be seen, and the albumin/globulin ratio is commonly less than 1.0. Concomitantly and
directly related to the reduced serum protein, hypocalcemia is found frequently, as reflected in
reduced total and ionized fractions. However, hypocalcemia rarely is manifested clinically. Of
much greater significance than hypocalcemia to patients who have nephrotic syndrome is the
increased concentrations of coagulation factors, especially those of highmolecular weight.
Thrombin also is increased, while fibrinolytic activity and circulating quantities of platelet
adhesion inhibitors are decreased. As a consequence of these changes, as well as the
intravascular hypovolemia, affected patients are at greatly increased risk of thrombosis. In
7/29/2019 SRNS Lapkas Sham & Justin
14/35
addition, IgG in plasma is reduced, which in combination with large steroid doses, may
predispose to infection. Children who become oliguric fromdiminished intravascular volume
have a tendency to develop hyperkalemia. The use of diuretics may complicate the electrolyte
disturbances further, necessitating close monitoring of serum electrolyte levels during treatment
(Roth KS et al, 2002).
2.7.3. The Need for a Renal Biopsy
In the acute stage of childhood nephrotic syndrome, especially during the initial episode, renal
biopsy usually is unnecessary. The key indications for biopsy in any renal disorder are the need
to make a specific diagnosis for therapeutic reasons or to provide a prognosis. The treatment of
initial-onset nephrotic syndrome is the same, irrespective of cause, and the need for determining
a prognosis never can outweigh the risks of thrombosis, bleeding, and infection due to a biopsy
in the acute stage of the disorder (Roth KS et al, 2002).
The subsequent disease course in a patient can help to determine the timing of a renal biopsy. In
an uncomplicated case in which proteinuria clears within a few weeks in response to orally
administered corticosteroids and normal renal function, the diagnosis is presumed to be minimal-
change nephrotic syndrome. If there is no significant proteinuria between relapses that continue
to respond promptly to corticosteroids, this diagnosis is strengthened. If the child is younger than
10 years of age at the initial presentation, no renal biopsy need be considered. At age 10 years or
older, the increasing risk of underlying primary disease compels the need to obtain a biopsy for
histologic diagnosis. In such cases, renal biopsy can be deferred until the child is stable and the
familys anxieties over the immediate medical problems have dissipated (Roth KS et al, 2002).
In contrast, when there is poor or no response of the initial episode after 4 to 6 weeks of standard
treatment (defined as steroid-resistance disease), biopsy should be considered as soon as the
patient is medically stable. In such cases, the biopsy is essential to distinguish the nature and
severity of the glomerular process, which may be primary or secondary (Table 3). It should be
clear from the plethora of types and causes of glomerular nephropathy that treatments and
prognoses vary considerably, making specific diagnosis imperative. Because proteinuria and
microscopic hematuria are injury responses of the glomerulus, the need for clarification through
renal biopsy is plain. (Roth KS et al, 2002).
7/29/2019 SRNS Lapkas Sham & Justin
15/35
Beyond the issue of renal biopsy for initial diagnosis, there are circumstances in which a
subsequent biopsy may be considered. Glomerular injury may evolve over time such that the
clinical findings (eg, increasing proteinuria, development of chronic renal insufficiency) change
significantly. Such cases may represent progression of a disease that initially was diagnosed as
minimal-change nephrosis by biopsy or progressive injury to the kidney by an underlying disease
such as lupus nephropathy. In these situations, a second renal biopsy should be considered for
evaluation of progressive renal disease. Technological developments in ultrasonography have
reduced significantly the risk associated with percutaneous renal biopsy in children. Moreover,
the improvements in electron microscopy equipment and technique, coupled with decades of
observation, have enhanced the ability of the histopathologist to interpret the specimen
accurately. Nonetheless, a renal biopsy is not always essential to good medical care, and its use
should be viewed judiciously in all patients (Roth KS et al, 2002).
2.8. TREATMENT OF NEPHROTIC SYNDROME
Before steroid treatment started, the following examinations must be conducted:
i. Measurement of weight and height
ii. Measurement of blood pressure
iii. Physical examination to look for signs or symptoms of systemic diseases, such as SLE,
Henoch-Schonlein Purpura
iv. Finding focus of infection in the teeth, ears, or worm infections. Each infection have to be
eradicated before start of steroid therapy
v. Mantoux test. If the result is positive, given INH prophylaxis for 6 months with steroids,
and if found tuberculosis, administered antituberculosis drugs.
2.8.1. Spesific Treatment
A. Treatment for Initial Therapy
1) Prednisone
When the diagnosis of nephrotic syndrome has been made, prednisone treatment can be started
in children with typical features. Children with atypical features should be referred to pediatric
nephrology for consideration of renal biopsy.
7/29/2019 SRNS Lapkas Sham & Justin
16/35
There is increasing evidence that longer initial courses of prednisone are associated with a lower
incidence of relapse, and therefore a 12-week initial course is recommended. The dose of
prednisone is based on surface area.
60 mg/m2/day for 4 weeks (maximim 80 mg)
40 mg/m2/on alternate days for 4 weeks (maximum 60mg)
Reduce dose by 5-10mg/m2 each week for another 4 weeks then stop
Prednisone can be given as a single dose in the morning with food, or as divided doses during the
day. Patients should be issued with a steroid warning card, and they should be aware of the side
effects and risks of steroid treatment. If prednisone causes gastric irritation, start ranitidine 2
mg/kgBW bid for the duration of steroid treatment.
2) Albumin
The clinical indications for albumin are:
Clinical hypovolaemia
Symptomatic oedema
A low serum albumin alone is not an indication for intravenous albumin. If there is evidence of
hypovolaemia, give 1 g/kg 20% albumin (5ml/kg) over 4 - 6 hours. Give 2 mg/kg of iv
furosemide mid-infusion. If clinically shocked give 10ml/kg 4.5% albumin. Children should be
closely monitored during albumin infusions, and where possible they should be administeredduring working hours.
3) Penicillin Prophylaxis
Whilst nephrotic, children are at increased risk of infection, particularly with encapsulated
organisms such as pneumococcus. There is no evidence that antibiotic prophylaxis is of benefit,
and some centres do not use prophylaxis. Penicillin V can be given while there is proteinuria and
discontinued when the child goes into remission. Grossly oedematous children are at risk of
cellulitis and may benefit from antibiotic prophylaxis. Dose for under 5 years old is 125 mg bid
and for 5 years or above is 250 mg bid.
4) Salt/Fluid Restriction
7/29/2019 SRNS Lapkas Sham & Justin
17/35
A low salt diet is used to try to prevent further fluid retention and oedema. Fluid restriction may
also be helpful. These restrictions are lifted once the child goes into remission.
5) Vaccination
Pneumococcal vaccination is recommended for children with NS. Consider giving at the time of
diagnosis. Varicella vaccination is only available on a named patient basis.
2.8.2 Treatment for Relapse Nephrotic syndrome
The patient should be examined for infections, which should be treated before initiating steroid
therapy. Appropriate therapy of an infection might rarely result in spontaneous remission,
thereby avoiding the need for treatment with corticosteroids. Antibiotic for infections should be
given 5-7 days.
Prednisone is administered at a dose of 2 mg/kg/day (single or divided doses) until urine protein
is trace or nil for three consecutive days (maximal for 4 weeks). Subsequently, prednisone is
given in a single morning dose of 1.5 mg/kg on alternate days for 4 weeks, and then
discontinued. The usual duration of treatment for a relapse is thus 5-6 weeks. Prolongation of
therapy is not necessary for patients with infrequent relapses. In case the patient is not in
remission despite two weeks treatment with daily prednisone, the treatment is extended for 2
more weeks. Patients showing no remission despite 4 weeks treatment with daily prednisone
should be referred for evaluation.
2.8.3. Treatment for Frequent Relapse or Steroid Dependence Nephrotic Syndrome
There are 4 options for treatment frequent relapse or steroid dependence nephrotic syndrome
- Long term Steroid
Full dose prednisone is given then continued by alternating dose, 1,5 mg/kgBW. This regiment is
decreased tapperingly 0,2 mg/kgBW each 2 weeks. Dose reduction is performed up to the
smallest dose that does not cause relapse of between 0.1 to 0.5 mg / kg alternating. This dose is
called the thershold dose and can be maintained for 6-12 months, then tried to stop.
When relapse occurred at doses between 0.1-0.5 mg/kgBB alternating, it will be treated with
prednisone 1 mg/kgBB in divided doses, given every day until remission occurs. After remission,
the prednisone was reduced to 0.8 mg/kgBW administered in alternating, then lowered to 0.2
7/29/2019 SRNS Lapkas Sham & Justin
18/35
mg/kgBW every 2 weeks, until one phase (0.2 mg/kgBW) in the dose of prednisone at the time
of relapse previous or the last relapse.
- Levamisole
Levamisole is administered at a dose of 2-2.5 mg/kg on alternate days for 4-12 months. Co-
treatment with prednisone at a dose of 1.5 mg/kg on alternate days is given for 2-4 weeks; its
dose is gradually reduced by 0.15-0.25 mg/kg every 4 weeks to a maintenance dose of 0.25-0.5
mg/kg that is continued for six or more months. Occasionally, it might be possible to discontinue
treatment with corticosteroids. The chief side effect of levamisole is leukopenia; flu-like
symptoms, liver toxicity, convulsions and skin rash are rare. The leukocyte count should be
monitored every 12-16 weeks.
- Cytostatistics Agent
Cytostatics agent that most commonly used in the treatment of nephrotic syndrome are
cyclophosphamide (CPA) or chlorambucil. Cyclophosphamide can be administered orally at a
dose of 2-3 mg/kgBW/day in single dose, or intravenously or puls. Puls CPA administered at a
dose of 500-750 mg/m2 BSA, which was dissolved in 250 ml NaCl 0,9% solution, administered
over 2 hours. Puls CPA administered doses of 7 times, with 1-month intervals (total duration of
CPA puls administration is 6 months). Side effects of CPA are nausea, vomiting, bone marrow
depression, alopecia, hemorrhagic cystitis, azoospermia, and in the long term can lead to
malignancy. Therefore need to monitor the examination of peripheral blood hemoglobin,
leukocytes, platelets, each 1-2 times a week. When the number of leukocytes
7/29/2019 SRNS Lapkas Sham & Justin
19/35
In the steroid-sensitive nephrotic syndrome who do not respond to levamisole or cytostatic can
be given MMF. MMF administered at a dose of 800-1200 mg/m2 BSA or 25-30 mg/kgBW
together with a reduction in steroid dosage for 12-24 months. MMF side effects are abdominal
pain, diarrhea, leucopenia.
Idiopathic nephrotic syndrome that is unresponsive to steroid treatment or cytostatics suggested
to cyclosporine administration at a dose of 4-5 mg/kgBW/day (100-150 mg/m2 BSA). The dose
of cyclosporine to maintain blood levels between 150-250 ng/ml. On frequent relapse nephrotic
syndrome or steroid dependent, CYA can cause and maintain remission, so that the steroid can
be reduced or stopped, but when CYA discontinued, relapse will usually return (dependent
cyclosporine).
2.8.4. Treatmet for Steroid Resistance Nephrotic Syndrome
For steroid resistance nephrotic syndrome, the treatment is
Oral cytostatic: cyclophosphamide 2-3 mg/kgBW/day single dose for 3-6 months.
Predison alternating doses of 40 mg/m2 BSA/day for oral administration of
cyclophosphamide. Later prednisone in tapering-off with a dose of 1 mg/kgBW/day
for 1 month, followed by 0,5 mg/kgBW/day for 1 month (long tapering-off of 2
months).
OR
Puls cyclophosphamide at a dose of 500-750 mg/m2 BSA given by intravenous
infusion or once a month for 6 months which may be continued depending on the
patient.
Prednisone alternating doses of 40 mg/m2 BSA/day for administrating
cyclophosphamide puls (6 months). Later prednisone in tapering-off with a dose of 1
mg/kgBW/day for 1 month, followed by 0,5 mg/kgBW/day for 1 month (long
tepering-off 2 months).
2.8.5. Nonspesific Treatment
7/29/2019 SRNS Lapkas Sham & Justin
20/35
A. Diets
A balanced diet, adequate in protein (1.5-2 g/kgBW) and calories is recommended. Patients with
persistent proteinuria should receive 2-2,5 g/kgBW of protein daily. Not more than 30% calories
should be derived from fat and saturated fats avoided. While salt restriction is not necessary in
most patients with steroid sensitive nephrotic syndrome, reduction of salt intake (1-2 g per day)
is advised for those with persistent edema. Salt should not be added to salads and fruits, and
snacks containing high salt avoided. Since treatment with corticosteroids stimulates appetite,
parents should be advised regarding ensuring physical activity and preventing excessive weight
gain.
B. Diuretics
Fluid restriction is recommended as long as there is severe edema. Usually given loop diuretics
such as furosemide 1-3 mg/kgBW/day, if necessary combined with spironolactone (aldosterone
antagonists, potassium-sparing diuretic) 2-4 mg/kgBW/day. Before administration of diuretics, it
should be excluded the possibility of hypovolemia. On diuretic use more than 1-2 weeks is
necessary to monitor blood electrolytes potassium and sodium. If diuretic administration did not
succeed (refractory edema), it usually occurs because of severe hypovolemia or
hypoalbuminemia ( 1 g/dL), albumin infusion may be given 20-25% at a dose of 1 g / kg for 2-
4 hours to draw fluid from the interstitial tissue and ends with the provision of intravenous
furosemide 1-2 mg / kg. If necessary, the suspension of albumin may be given alternate days to
allow a shift of fluid and prevent fluid overload. When ascites so severe that it interferes with
breathing, repeatedly ascites puncture can be performed.
2.9. COMPLICATION OF NEPHROTIC SYNDROME
7/29/2019 SRNS Lapkas Sham & Justin
21/35
Medical complications of nephrotic syndrome are potentially serious. They can be divided into
two major subgroups: acute complications related to the nephrotic state, especially infections and
thromboembolic disease, and long-term sequelae of nephrotic syndrome and its treatment,
especially effects on bones, growth, and the cardiovascular system. A third important area is the
psychological impact and social demands on children who have nephrotic syndrome, and their
families (Eddy AA, Symons JM, 2003).
2.9.1. Infectious complications
Serious infection, especially cellulitis and spontaneous bacterial peritonitis, can complicate
nephrotic syndrome. The rate of peritonitis is 26%, and overwhelming infection still carries a
mortality rate of 15%. Susceptibility to bacterial infection is related to multiple predisposing
factors (figure 4). Impaired complement-dependent opsonisation delays clearance of
encapsulated micro-organisms, especially Streptococcus pneumoniae (figure 4). Pneumococcal
vaccination is recommended for patients who have nephrotic syndrome. Prophylactic treatment
with penicillin during relapses has been suggested but few data support this practice. Patients are
also predisposed to gram-negative bacterial infections. Since many children with idiopathic
nephrotic syndrome are varicella non-immune, varicella exposure and infection require special
consideration. Prophylactic treatment with varicella zoster immune globulin is recommended for
non-immune patients taking immunosuppressive treatments. Once remission is achieved,
immunisation with varicella vaccine seems safe and effective, although additional doses may be
required to achieve full immunity. Concomitant use of oral aciclovir may also prevent serious
varicella infection in patients receiving corticosteroids (Eddy AA, Symons JM, 2003).
2.9.2. Thromboembolic complications
Nephrotic patients are at significantly increased risk of thrombosis, with complication rates
reported as high as 40% in adults. Although thrombosis risk is apparently lower in nephrotic
children (1850%), these events can be severe. Multiple factors contribute to the dysregulated
coagulation state of nephrotic syndrome (figure 5). No one laboratory test can reliably predict the
real thrombotic risk. Fibrinogen concentration has been proposed as a surrogate marker. Other
factors that increase thrombotic risk in nephrotic patients include diuretic use, corticosteroid
treatment, immobilisation, and the presence of in-dwelling catheters. If a clot is noted in a
7/29/2019 SRNS Lapkas Sham & Justin
22/35
nephrotic child, investigation for an inherited coagulation abnormality is still recommended
(Eddy AA, Symons JM, 2003).
Prophylactic anticoagulation is not recommended because of its own inherent risks. However,
after treatment of a documented clot, use of prophylactic warfarin has been recommended for at
least 6 months, and perhaps during future relapses. In-dwelling venous catheters should be
avoided, but if absolutely necessary, prophylactic anticoagulation should be considered. Low-
molecular-weight heparin is an attractive alternative agent, but it requires sufficient antithrombin
III substrate to be effective. Aspirin may also be considered for anticoagulation, especially if
thrombocytosis is severe (Eddy AA, Symons JM, 2003).
2.9.3. Cardiovascular disease
Multiple factors raise concerns for cardiovascular sequelae in children with long-term nephrotic
syndrome, including exposure to corticosteroids, hyperlipidaemia, oxidant stress, hypertension,
hypercoagulability, and anaemia (erythropoietin-responsive anaemia is a rare complication).
Nephrotic syndrome in adulthood is associated with an increased risk of coronary heart disease.
Myocardial infarction in young children with nephrotic syndrome has been reported, but the
relative risk has not been calculated. In adults with nephrotic syndrome, HMG-CoA reductase
inhibitors can control hyperlipidaemia and limit its complications. Whether or not to treat
hyperlipidaemia in nephrotic children has been a source of controversy, especially since most
children have treatable renal disease. Adequate safety and efficacy data for HMG-CoA-reductase
inhibitors in children are not available, despite small case series in which decreased serum lipids
have been reported. Persistent hyperlipidaemia in unremitting childhood nephrotic syndrome is
concerning, but there is little evidence as yet to guide treatment or predict future outcome (Eddy
AA, Symons JM, 2003).
2.9.4. Other medical complications
Despite theoretical risks of bone-density reduction with corticosteroid use, the prevalence of
bone disease in children with nephrotic syndrome is not yet clear. In addition to steroids, there
are other potential causes of bone disease in nephrotic syndrome. Urinary loss of vitamin-D-
binding protein, a 59 kd carrier protein for 25-hydroxycholecalciferol, may cause vitamin D
deficiency and, less commonly, secondary hyperparathyroidism. Other potential medical
7/29/2019 SRNS Lapkas Sham & Justin
23/35
complications include drug toxic effects, hypothyroidism and acute renal failure. Although
diuretics and albumin infusions can successfully treat symptomatic oedema, injudicious use can
lead to either acute volume overload or intravascular depletion, dependent on the cause of
oedema (Eddy AA, Symons JM, 2003).
2.10. PROGNOSIS OF NEPHROTIC SYNDROME
The most important prognostic indicator in nephrotic syndrome is steroid responsiveness.
Overall, 6080% of steroid-responsive nephrotic children will relapse and about 60% of those
will have five or more relapses. Age older than 4 years at presentation and remission within 79
days of the start of steroid treatment in the absence of micro haematuria are predictive of fewer
relapses. In a natural-history study of 398 children, the proportion that became non-relapsers rose
from 44% at 1 year to 69% at 5 years, and 84% at 10 years. For the steroid-resistant FSGS
patients, the clinical course is typically very challenging. With current treatments, a few children
will ultimately achieve a sustained remission with one of the second-line or third-line drugs. For
patients with refractory nephrotic syndrome, progression to end-stage renal disease is inevitable.
Some of these children have such a difficult clinical course because of refractory oedema, severe
infections, thromboembolic complications, or a combination of these, that bilateral
nephrectomies and dialysis provide welcome relief. For this subgroup, the ultimate treatment
goal is renal transplantation, despite the haunting reality that FSGS will recur in about 25% of
renal allografts. For patients who have familial forms of nephrotic syndrome,
immunosuppressive treatment is ineffective; definitive treatment requires renal transplantation.
Most of these patients do well after transplantation. Although the original genetic renal disease
does not recur in the renal allograft, nephrotic syndrome has been noted in a subset of patients as
a consequence of immunological attack on a new antigen encountered for the first time in the
transplanted kidney (eg, injury mediated by antibody to nephrin in children with congenital
nephrotic syndrome). Although much has been learned about the management of childhood
nephrotic syndrome, this chronic disorder remains challenging. Advances in molecular genetics
offer hope of new pathogenetic insights. Multicentre clinical trials are needed to improve current
treatments and prevent acute and long-term complications (Eddy AA, Symons JM, 2003).
2.11. DEFINITION OF STEROID-RESISTANT NEPHROTIC SYNDROME
7/29/2019 SRNS Lapkas Sham & Justin
24/35
Among pediatric nephrologists there are two definitions of steroid-resistant nephrotic syndrome
(SRNS). The definition introduced by the International Study of Kidney Disease in Children
(ISKDC) and used by the Arbeitsgemeinschaft fr Pdiatrische Nephrologie (APN) is widely
accepted as follows:
No urinary remission within 4 weeks of prednisone therapy 60mg/m2/day.
The other definition, employed by the Society of French Speaking Pediatric Nephrologists,
states:
No urinary remission following 4 weeks of prednisone 60mg/m2/day followed by three
intravenous pulses of methylpredisolone.
The rationale for both definitions is the experience that almost all patients with minimal change
who respond will do so within 4 weeks (Figure 16-1) and only a small percentage will respond
later (often called late responders). It is of great importance for interpretation of clinical data and
studies to know the patients age and the definition used.
2.12. EPIDEMIOLOGY OF STEROID-RESISTANT NEPHROTIC SYNDROME
The incidence of SRNs varies throughout the world. The incidence of minimal change versus
other histologies in patients biopsied because of nephrotic syndrome varies among children and
adults and among children from the Northern Hemisphere and those from Africa. There are also
different patterns in South America and Asia. It should be kept in mind that these comparisons
are relative, because the initial therapy with steroids cannot be compared between children and
adults. Furthermore there are no data about how different pharmacogenetic backgrounds and
therapeutic doses of prednisone with different pharmacokinetic and pharmacodynamic profi les
infl uence response to treatment. In addition, race appears to have an important impact on the
histology associated with nephrotic syndrome. Although the incidence of nephrotic syndrome
has remained stable over the last 30 years, evidence from the literature suggests that the total
number of patients with focal segmental glomerulosclerosis (FSGS) is increasing, especially in
South Africa and India.
A weak predictor for the probability of FSGS as opposed to minimal change nephrotic syndrome
(MCNS) is age. In children with MCNS, about 80% are diagnosed before the age of 6 compared
with 50% of those with FSGS lesions in histology.
PATHOGENESIS OF STEROID-RESISTANT NEPHROTIC SYNDROME
7/29/2019 SRNS Lapkas Sham & Justin
25/35
As described in earlier chapters, the key element in the pathogenesis of proteinuria in nephrotic
syndrome is the podocyte. Since the discovery of a mutation in the nephrin gene in patients with
congenital nephrotic syndrome of the Finnish type, the biology of the podocyte has become a
center of interest. With the description of new gene mutations and altered gene products
responsible for the structure function and signaling of podocytes, understanding of diseases with
proteinuria has increased; however, with more knowledge, the number of questions has also
increased. In general, one can distinguish two mechanisms leading to proteinuria: con-
genital and acquired.
During embryonic development, the outer part of the GBM is made by podocytes. Major
podocytes need a full complement of proteins for building up complex structures as well as for
signaling (Figure 16-5). A major function of podocytes is to perform as a buttress against the
pressure of the glomerular capillaries. Any stress and functional impairment, as well as podocyte
loss, may compromise the filtration barrier and lead to proteinuria.
It is logical that congenital defects may be somewhat resistant to any kind of pharmacologic
treatment. In acquired diseases the major goal should be eliminating the cause of podocyte
injury, as well as allowing the podocytes to recover and restoring their function after injury.
Since podocytes have not been shown to replicate, any loss must be compensated by those
remaining. Continuing podocyte loss may be critical below a certain threshold, which is
estimated as a loss of more than 20% (Figure 16-6). As shown by Kriz and others, a decreasing
podocyte number leads to denuded GBM areas that will come into contact with the parietal
epithelial cells lining Bowmans capsule by force of the intracapillary pressure. Once sclerotic
lesions are established, a point of no return for these lesions is reached. Misdirected filtration
(Figure 16-7) via the glomerular basement areas attached to Bowmans capsule and into the
periglomerular and peritubular interstitium leads to infl ammation and scarring of the renal
cortex. Therefore any treatment should try to regenerate podocyte function before sclerotic
lesions appear. It is amazing that the classical hypothesis of the immortal podocyte has never
been questioned. The fact that a cell with such a highly developed structure should live for
almost 70 years is doubtful. If there is podocyte turnover, it might be so low that it has escaped
the attention of investigators. To what extent stem cells might contribute to podocyte turnover
has to be studied. However, such a possibility may be attractive for future therapeutic
approaches. The inflammatory changes leading to tubulointerstitial scarring should be regarded
7/29/2019 SRNS Lapkas Sham & Justin
26/35
as an important part of this disease leading to end-stage renal failure. The understanding of such
processes, especially the epithelial mesenchymal transition (EMT), is of great interest. A detailed
understanding may provide a rationale for specific interventions in the future. Until then,
nonspecific immunosuppressive effects that dampen this process are used.
GENETICS OF STEROID-RESISTANT NEPHROTIC SYNDROME
An overview of the variety of conditions associated with FSGS is given in Table 16-2, and recent
advances in genetics and mutations associated with SRNS are covered in Chapter 13. Recently
Hinkes 12 described a new mutation leading to SRNS, called NPHS3. The gene product is
phospholipase Cepsilon (PLCE1). This mutation causes early-onset nephrotic syndrome leading
to end-stage kidney disease in young children. Kidney histology of affected individuals show
diffuse mesangiosclerosis (DMS). The gene product is expressed in the developing kidney in
mature glomerular podocytes, which has been shown to lead to an arrest of normal glomerular
development. Interestingly, a few patients with this mutation might respond to
immunosuppressive therapy.
SRNS may be part of syndromatic diseases as listed in Table 16-2 (see examples, Figures 16-8
and 16-9). Careful clinical examination is essential to rule out minor abnormalities suggestive of
syndromatic forms of nephrotic syndrome to avoid unnecessary steroid treatment. In many cases,
however, steroid therapy will start first and genetic investigations will be initiated only if steroid
resistance has been confirmed by the classical definition. In the clinical day-to-day practice there
is sometimes a tremendous delay between the request for genetic testing and when the result will
be available. Because there are no markers predicting a gene defect, many patients may undergo
further immunosuppressive therapy until a clear diagnosis is established.
During this time, any therapy with irreversible or severe side effects should be avoided. Up to
now it has been shown that immunosuppressive therapy is of no value in patients with NPHS1,
NPHS2, WT1, and TRPC6 mutations. Ruf et al have reported that out of 165 families with
SRNS, 43 (26%) showed homozygote or compound heterozygote mutations in the NPHS2 gene
(podocin). In contrast, no mutations were found in 120 families with steroid-sensitive nephrotic
syndrome. None of the patients with homozygous or compound heterozygous mutations in the
NPHS2 gene who were treated with cyclosporine or cyclophosphamide demonstrated complete
remission of the nephrotic syndrome. The geographic variation of NPHS2 mutations is of
7/29/2019 SRNS Lapkas Sham & Justin
27/35
importance. Maruyama et al. reported that mutations in the NPHS2 gene are uncommon in
Japanese pediatric patients with SRNS.
NONGENETIC FSGSOF STEROID-RESISTANT NEPHROTIC SYNDROME
There is evidence from many clinical observations that a circulating factor targets the kidney,
leading to proteinuria and glomerular sclerotic lesions. Most striking are observations about the
recurrence of proteinuria within hours after renal transplantation in some patients who had end-
stage renal failure with FSGS. The nature of the factor has yet to be defined. Some call it the
Savin factor, because major work has been carried out by Virginia Savin and her group to isolate
it. This factor is believed to be removable by plasma separation, and anecdotal data on successful
treatment after recurrence of FSGS post-transplant support this possibility. Some clinical
observations point toward suppressive effects with the use of immunosuppressive drugs,
especially calcineurin inhibitors. Such concepts are attractive treatment strategies; however, no
reliable tests for identifying such a factor have been elaborated.
TREATMENTOF STEROID-RESISTANT NEPHROTIC SYNDROME
A review of the current literature about treatment of children with SRNS reveals that many
children with familial or syndromic FSGS or with the known mutations still receive too much
immunosuppressive therapy either initially or after an escalation with current available
immunosuppressive drugs. A metaanalysis of randomized controlled prospective trials in SRNS
with FSGS without genetic testing demonstrates that cyclosporin may lead to a complete
remission in almost one third of children. In contrast, neither oral nor intravenous
cyclophosphamide demonstrates any effect on remission. A major problem in reviewing the
literature was that most studies were nonrandomized and retrospective, with low numbers of
patients. In approximately two thirds of the studies, the number of patients was less than 10.
Other studies have included both children and adults with MCNS and mesangial proliferation.
The fact that different age groups may have different underlying diseases has been ignored. A
further problem is that the steroid therapy used, as well as the definitions, did not meet the
international accepted standards. Most studies focused on short-term effects, and long-term
studies are lacking. In children, attention should be focused on side effects of therapy and
comorbidity, such as impaired growth and body configuration.
7/29/2019 SRNS Lapkas Sham & Justin
28/35
Specific Agents
Glucocorticosteroids
In the early 1990s, Mendoza et al. treated patients with SRNS due to FSGS with a protocol
involving infusions of high doses of methylprednisolone, often in combination with oral
alkylating agents. Twenty-three children have been treated in this manner, with a follow-up of 46
+/ 5 months. Twelve of them went into complete remission, six had minimal to moderate
proteinuria, and four remained nephrotic. Each had a normal glomerular filtration rate. One child
developed chronic renal failure and subsequently died while on dialysis. These results appear
significantly better than in previous series of children with FSGS. More cases have been added to
this first series, and the so-called Mendoza protocol has been used in many centers. However, a
prospective randomized controlled trial has never been published. Concerns about
methylprednisolone side effects left many clinicians reluctant to employ this protocol but
stimulated a search for new drugs allowing steroid sparing.
The mode of action of corticosteroids was speculative and unclear until recently. Experimental
data from Fujii et al. may offer new insights into possible mechanisms for efficacy. Fujii
demonstrated defective nephrin transport following endoplasmic reticulum-stress; that is,
endoplasmic reticulum stress in podocytes may cause alteration of nephrin N-glycosylation,
which may be an underlying factor in the pathogenesis of the proteinuria in nephrotic syndrome.
Dexa-methasone may restore this imbalance by stimulating expression of mitochondrial genes,
resulting in production of ATP, which is an essential factor for proper folding machinery aided
by the ER chaperones. It is unclear if there will be a place for dexamethasone in future
therapeutic proposals.
Calcineurin Inhibitors
Calcineurin inhibitors have been used more in an empirical manner than on the basis of clear
rationale. Cyclosporin is a calcineurin inhibitor that suppresses immune response by
downregulating the transcription of various cytokine genes. The most significant of these
cytokines is interleukin-2, which serves as the major activation factor for T cells in numerous
immunologic processes. Cyclosporin inhibits cytokine production from T helper cells (Th1 and
Th2) and also has an inhibitory effect on antigen-presenting cells (Langerhans and dendritic
7/29/2019 SRNS Lapkas Sham & Justin
29/35
cells), which are the main agents of T-cell stimulation. A further effect of interleukin-2 inhibition
is a reduction in B-cell activation and subsequent antibody production. Interleukin-2 levels are
known to become elevated during proteinuria and to normalize during remission in adults with
idiopathic nephrotic syndrome and in children with MCNS or FSGS.
However, this pattern of interleukin-2 activity is felt to be part of a more widespread disorder of
cellular immunity that results in nephrotic syndrome rather than being causal of proteinuria. It
has been reported that cyclosporin has some antiproteinuric action on glomerular perm
selectivity to proteins that is unrelated to its immunosuppressive properties. Among these are an
influence on perm-selectivity and charge selectivity, and impairment of glomerular filtration rate.
These data come from various human studies and animal models with no immunologically
mediated disease. Some studies revealed that lesions from the primary glomerular disease had
either not regressed or had continued to progress.
An uncontrolled trial in the early 1990s showed that about half of the patients had a stable course
during cyclosporin treatment, whereas the others were resistant to the treatment (Figure 16-10).
Knowledge of the various genetic and nongenetic causes of SRNS might easily explain this
difference in response.
The first controlled data about efficacy of cyclosporin in SRNS came from Lieberman and
Tejani: they performed a randomized double-blind placebo-controlled trial of cyclosporin in 25
children with steroid-resistant idiopathic FSGS. Cyclosporin significantly reduced proteinuria
and increased serum albumin levels. Interestingly, hypercholesterolemia seemed to antagonize
the effect of cyclosporin, leading to the proposal to increase the dose according to cholesterol
levels.
This has been cited in the literature quite often, but apparently has not been translated into
clinical use as discerned from review of the literature. Major concerns were the nephrotoxic side
effects of cyclosporin, as well as a fear that progression of the disease might be indistinguishable
from toxicity. The French Society of Pediatric Nephrology published its experience with 65
children with steroid-resistant idiopathic nephrosis. Patients were treated with cyclosporin at 150
to 200 mg/m2 in combination with prednisone at 30 mg/m2 daily for 1 month and on alternate
days for 5 months. Renal biopsy showed minimal change disease in 45 children and FSGS in 20.
Twenty-seven patients achieved complete remission.
7/29/2019 SRNS Lapkas Sham & Justin
30/35
A study in adult patients provided Level I evidence for efficacy of cyclosporin. In this study a
26-week regimen of cyclosporin therapy was compared with placebo in 49 patients with steroid-
resistant FSGS; both groups also received low-dose prednisone. Further evidence was provided
by Ponticelli et al.
Cyclosporin was compared to symptomatic treatment in 44 patients (adults and children) with
SRNS. Eight (57%) cyclosporin-treated patients attained remission (complete or partial). Three
(16%) control patients had partial remissions, but details regarding their diagnoses were
incomplete. The majority of remitters had relapsed by the end of month when cyclosporin was
stopped.
The Arbeitsgemeinschaft fr Pdiatrische Nephrologie (APN) conducted a prospective
randomized trial that included children with SRNS at initial manifestation. Six months of
treatment with cyclosporin (trough level 80 to 120 ng/L) versus 6 months of treatment with
cyclophosphamide (6 500 mg/m2) were compared. Although the goal was to involve 60
patients, the study was stopped after the inclusion of 32. A complete remission was achieved in 2
out of 15 receiving cyclosporin and in 2 out of 17 receiving cyclophosphamide; a partial
remission was obtained in 7 out of 15 versus 2 out of 17. It was concluded that initial response
with cyclosporin was better than with cyclophos phamide pulses (60% vs. 17%). Complete
remission after week 24 was similar in both groups. In those who did not respond to
cyclophosphamide, a successful remission was achieved in 45% with cyclosporin. Safety in both
arms was comparable.
Recently Franz and colleagues presented data that cyclosporin protects podocyte stress fi bers
through stabilization of synaptopodin protein expression. If this is supported by future
experimental data, a nonimmunologic approach for the treatment might be envisaged. A pilot
trial of tacrolimus in the management of SRNS was published by McCauley et al. in 1993. All
patients except one experienced at least a 50% reduction in protein excretion at some time during
tacrolimus therapy. No controlled study has been carried out, and only uncontrolled experiences
have been published. Loeffl er reported a series of 16 patients resistant to other
immunosuppressive drugs. In this mixed group he concluded that tacrolimus is an effective,
well-tolerated medication for treatment-resistant forms of nephrotic syndrome in children,
resulting in a complete remission rate of 81% and a partial remission rate of 13%.
7/29/2019 SRNS Lapkas Sham & Justin
31/35
More data and a prospective trial are needed to confirm these promising results and to
demonstrate the safety of this approach. As of now, of the newer immunosuppressive agents only
cyclosporin has been approved for use in nephrotic syndrome by licensing authorities in some
countries. An algorithm for the use of cyclosporin in SRNS (Figure 16-11) has been proposed.
(Result of an expert meeting, London, 2005.)
Antiproliferative Agents
Azathioprine and vincristine have been used by some individuals but have not been widely
recommended because of the lack of positive results. Cyclophosphamide has failed to prove any
benefit, although many investigators have included this drug in their armamentarium. In most of
the reports, drug combinations were employed that did not allow separation of single drug
effects. The prospective trial of the APN mentioned earlier was stopped because of the inferiority
of cyclophosphamide to cyclosporin.
Mycophenolate mofetil (MMF) has attracted investigators interest because of its nonnephrotoxic
profi le. Some uncontrolled trials point toward possible benefi ts, but (a) the lack of control
data, (b) the anecdotal character, (c) the possible selection bias in reporting, and (d) the fact that
this drug has been in routine use for more than 10 years in the transplant setting but no robust
data are available demonstrating any effect for prevention of posttransplant recurrence of
7/29/2019 SRNS Lapkas Sham & Justin
32/35
original disease all argue against premature recommendations. One should await the results of
the trial being undertaken in the United States under the auspices of the National Institutes of
Health, wherein treatment with cyclosporin over 26 weeks will be compared with MMF/pulse
steroids and continued for 52 weeks if response of proteinuria occurs. Both treatment arms
include low-dose prednisone and ACE inhibitor therapy. Patients will be recruited at more than
130 sites in North America.
Antiproteinuric Treatment
There is strong evidence from studies in adult patients that ACE inhibitors effectively lower
proteinuria in various diseases involving proteinuria. These results have been accepted by many
pediatric nephrologists as a robust argument for introducing ACE inhibitors for their patients
with proteinuria. The dilemma is that in pediatric patients this has led to off-label use without
proper phase II and III trials. A large series of pediatric patients have been treated with ramipril
in the Escape Triala prospective assessment of the renoprotective efficacy of ACE inhibition
and intensified blood pressure control. In this assessment, 397 children (ages 3 to 18 years) with
chronic renal failure (GFR 11 to 80 ml/min/1.73m2) and elevated or high-normal BP received
ramipril (6 mg/m2) following a 6-month run-in period, including a 2-month washout of any
previous ACE inhibitors.
Blood pressure was reduced with equal efficacy daytime and nighttime. Urinary protein
excretion was reduced by 50% on average, with similar relative efficacy in patients with
hypo/dysplastic nephropathies and glomerulopathies. The magnitude of proteinuria reduction
depended on baseline proteinuria (r = 0.32, p < 0.0001), and was correlated with the
antihypertensive effi cacy of the drug (r = 0.22, p < 0.001). Small, uncontrolled trials in
pediatric patients with persistant nephritic syndrome also found some reduction of proteinuria.
The positive interpretation of a renoprotective effect of ACE inhibitors with and without AT1
receptor antagonist has made it unlikely that children are left without such treatment.
7/29/2019 SRNS Lapkas Sham & Justin
33/35
(Bagga A, Management of Steroid Resistant Nephrotic Syndrome, Indian Society of Pediatric
Nephrology, Volume 46, January 17, 2009)
PROGNOSIS OFSTEROID-RESISTANT NEPHROTIC SYNDROME
Steroid-resistant nephrotic syndrome is not a single entity. The most dominant lesion is focal
segmental glomerulosclerosis (FSGS). Better understanding of the underlying diseases and
mechanisms will guide future treatment. Early genetic diagnosis might help to avoid ineffective
but harmful immunosuppressive therapy (Hoyer PF et al, 2008)
7/29/2019 SRNS Lapkas Sham & Justin
34/35
REFERENCES
1. Karl S. Roth, Barbara H. Amaker and James C.M. Chan, Nephrotic Syndrome: Pathogenesis
and Management, Pediatr. Rev. 2002;23;237
2. Allison A Eddy, Jordan M Symons., Nephrotic syndrome in childhood, The Lancet, Vol 362,
August 23, 2003
7/29/2019 SRNS Lapkas Sham & Justin
35/35
3. Bruce M. Tune, Stanley A. Mendoza, Treatment of the Idiopathic Nephrotic Syndrome:
Regimens and Outcomes in Children and Adults, Journal of the American Society of
Nephrology, 1997
4. Fahmi, N., Nephrotic Syndrome, Banghdad Medical College, 2011
5. Arvind Bagga & Mukta Mantan, Nephrotic syndrome in children, Review Article Indian J
Med Res 122, July 2005, pp 13-28
6. Miller Christopher A, Patrick T. OGara, Leonard S. Lily. Nephrotic Syndrom in Childhood.
Sudoyo, Aru W, dkk. Buku Ajar Ilmu Penyakit Dalam Jilid III Edisi IV. Jakarta: FK UI 2007;
1566-1571
7. Konsensus Tata Laksana Sindrom Nefrotik Idiopatik pada Anak Edisi 2,Unit Kerja Koordinasi
Nefrologi Ikatan Dokter Anak Indonesia, 2008
8. Peter F. Hoyer, Udo Vester, and Jan Ulrich Becker, Chapter 16 Steroid-Resistant Nephrotic
Syndrome, OMIN PubMed, 2008; 257-266
9.
Recommended